[go: up one dir, main page]

WO2018151840A3 - Methods and compositions for treating malignant tumors - Google Patents

Methods and compositions for treating malignant tumors Download PDF

Info

Publication number
WO2018151840A3
WO2018151840A3 PCT/US2018/000054 US2018000054W WO2018151840A3 WO 2018151840 A3 WO2018151840 A3 WO 2018151840A3 US 2018000054 W US2018000054 W US 2018000054W WO 2018151840 A3 WO2018151840 A3 WO 2018151840A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
mammal
methods
malignant tumors
kras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/000054
Other languages
French (fr)
Other versions
WO2018151840A2 (en
Inventor
Wenbin Ying
Kenjirou Minomi
Jihua Liu
Li Wang
Bharat Majeti
Roger Adami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/434,318 external-priority patent/US10792299B2/en
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Priority to JP2018535394A priority Critical patent/JP2019508379A/en
Publication of WO2018151840A2 publication Critical patent/WO2018151840A2/en
Publication of WO2018151840A3 publication Critical patent/WO2018151840A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.
PCT/US2018/000054 2017-02-16 2018-02-16 Methods and compositions for treating malignant tumors Ceased WO2018151840A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018535394A JP2019508379A (en) 2017-02-16 2018-02-16 Therapeutic method and therapeutic composition for malignant tumor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/434,318 2017-02-16
US15/434,318 US10792299B2 (en) 2014-12-26 2017-02-16 Methods and compositions for treating malignant tumors associated with kras mutation

Publications (2)

Publication Number Publication Date
WO2018151840A2 WO2018151840A2 (en) 2018-08-23
WO2018151840A3 true WO2018151840A3 (en) 2018-10-11

Family

ID=63170424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/000054 Ceased WO2018151840A2 (en) 2017-02-16 2018-02-16 Methods and compositions for treating malignant tumors

Country Status (2)

Country Link
JP (2) JP2019508379A (en)
WO (1) WO2018151840A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220331433A1 (en) * 2019-09-06 2022-10-20 The Regents Of The University Of California Nucleic acid-mediated delivery of therapeutics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160186182A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Rna interference compositions and methods for malignant tumors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101346393B (en) * 2005-11-02 2015-07-22 普洛体维生物治疗公司 Modified siRNA molecules and uses thereof
EP2194128B1 (en) * 2006-05-11 2012-08-01 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
ES2596584T3 (en) * 2007-07-05 2017-01-10 Arrowhead Research Corporation RRNA for treatment of viral infections
US20160187319A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth
JP6899201B2 (en) * 2016-06-23 2021-07-07 日東電工株式会社 Cell death inducer, cell proliferation inhibitor and therapeutic pharmaceutical composition for diseases caused by abnormal cell proliferation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160186182A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Rna interference compositions and methods for malignant tumors
US20160186183A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation

Also Published As

Publication number Publication date
WO2018151840A2 (en) 2018-08-23
JP2019033741A (en) 2019-03-07
JP2019508379A (en) 2019-03-28

Similar Documents

Publication Publication Date Title
WO2016106404A3 (en) Methods and compositions for treating malignant tumors associated with kras mutation
NZ763275A (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
PH12020500332A1 (en) Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
WO2019006418A3 (en) Adeno-associated viral vectors for gene therapy
MY206230A (en) Amyloid precursor protein (app) rnai agent compositions and methods of use thereof
EA201891268A1 (en) COMPOUNDS WHICH CAN BE USED AS KINASE INHIBITORS
WO2018140920A8 (en) Compositions and methods for inhibition of factor xii gene expression
WO2019067666A8 (en) Therapeutic methods relating to hsp90 inhibitors
WO2018098117A8 (en) SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
BR112016028641A2 (en) ? method for treating cancer?
EA201792103A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HIF2ALPH GENES
MX2023012048A (en) Compositions and methods for inhibiting ketohexokinase (khk).
IN2014DN08199A (en)
MX2019011506A (en) Combinations of chk1- and wee1 - inhibitors.
MX394425B (en) COMBINATION THERAPY WITH BROMODOMAIN AND EXTRA TERMINAL PROTEIN INHIBITOR.
MX2021008261A (en) Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use.
Wang et al. PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreatic cancer cell lines
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
BR112018011196A2 (en) use pyrimidine pyrimidazinones to treat cancer
BR112022007010A2 (en) GENE THERAPY FOR ALZHEIMER'S DISEASE
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof
WO2018151840A3 (en) Methods and compositions for treating malignant tumors
EP4516300A3 (en) Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n
WO2013066485A3 (en) Compositions and methods for treatment of metastatic cancer
WO2022115664A3 (en) Methods for treating cancer using combinations of epigenetic therapies and radioconjugate targeting agents

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2018535394

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18754969

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18754969

Country of ref document: EP

Kind code of ref document: A2